Products - Dementia | Topic

Showing 15 products

Date | Title

Suspected neurological conditions: recognition and referral (NG127)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
1 May 2019
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 June 2018
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 June 2018
Published:
23 March 2011
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 October 2015
Suspected neurological conditions: recognition and referral (QS198)
Product type:
Quality standard
Published:
8 January 2021
Dementia (QS184)
Product type:
Quality standard
Published:
28 June 2019
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2025
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
23 July 2025
Prevention of dementia
Status:
Awaiting development
Expected publication date:
TBC
Gantenerumab for treating early Alzheimer's disease [TSID10668]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Deep Brain Stimulation for Alzheimer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Pridopidine for treating Huntington's disease [ID6525]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [TSID12157]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Dementia Products

Showing 15 products

Suspected neurological conditions: recognition and referral (NG127)

Dementia: assessment, management and support for people living with dementia and their carers (NG97)

Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

Suspected neurological conditions: recognition and referral (QS198)

Dementia (QS184)

Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]

Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]

Prevention of dementia

Gantenerumab for treating early Alzheimer's disease [TSID10668]

Alzheimer's disease (early) - gantenerumab [ID6142]

Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

Deep Brain Stimulation for Alzheimer

Pridopidine for treating Huntington's disease [ID6525]

Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [TSID12157]

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Dementia Products

Showing 15 products